Poland: These 42 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Poland
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Poland: These 42 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
| Tradename | Ingredient | Estimated Entry Opportunity Date |
|---|---|---|
| CREON | pancrelipase (amylase;lipase;protease) | 2026-08-15 |
| EMBEDA | morphine sulfate; naltrexone hydrochloride | 2026-06-19 |
| ESBRIET | pirfenidone | 2026-09-22 |
| LYNPARZA | olaparib | 2026-10-17 |
| NINLARO | ixazomib citrate | 2027-08-06 |
| XALKORI | crizotinib | 2026-11-23 |
| PREPOPIK | citric acid; magnesium oxide; sodium picosulfate | 2027-10-12 |
| >Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Poland: These 42 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Poland Patent 1,931,316
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Poland Patent 1,931,317
CREON is a drug marketed by
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,034,975
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,484,346
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,526,932
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can EMBEDA (morphine sulfate; naltrexone hydrochloride) generic drug versions launch?
Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,719,378
EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.
This drug has seventy-four patent family members in twenty-three countries.
See drug price trends for EMBEDA.
The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Poland Patent 1,940,364
ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can LYNPARZA (olaparib) generic drug versions launch?
Generic name: olaparib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: Poland Patent 2,064,189
LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA
See drug price trends for LYNPARZA.
The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.
When can NINLARO (ixazomib citrate) generic drug versions launch?
Generic name: ixazomib citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: Poland Patent 2,178,888
NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.
This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO
See drug price trends for NINLARO.
The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 23, 2026
Generic Entry Controlled by: Poland Patent 1,963,302
XALKORI is a drug marketed by Pf Prism Cv. There are three patents protecting this drug.
This drug has one hundred and five patent family members in forty-six countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch?
Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 12, 2027
Generic Entry Controlled by: Poland Patent 2,207,526
PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering PREPOPIK
See drug price trends for PREPOPIK.
The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.
When can BYDUREON (exenatide synthetic) generic drug versions launch?
Generic name: exenatide synthetic
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Poland Patent 2,069,374
This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON
See drug price trends for BYDUREON.
The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: Poland Patent 2,046,318
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,450,035
This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO
See drug price trends for EPIDUO.
The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: Poland Patent 2,046,318
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can EPIDUO FORTE (adapalene; benzoyl peroxide) generic drug versions launch?
Generic name: adapalene; benzoyl peroxide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,450,035
See drug price trends for EPIDUO FORTE.
The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Poland Patent 1,988,877
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can VIZAMYL (flutemetamol f-18) generic drug versions launch?
Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 30, 2027
Generic Entry Controlled by: Poland Patent 2,182,988
VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.
This drug has twenty-three patent family members in twenty countries.
See drug price trends for VIZAMYL.
The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this generic product. Additional details are available on the flutemetamol f-18 profile page.
When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?
Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Poland Patent 2,164,473
SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.
See drug price trends for SIGNIFOR LAR.
The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: Poland Patent 2,004,196
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
When can LASTACAFT (alcaftadine) generic drug versions launch?
Generic name: alcaftadine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: Poland Patent 3,150,209
This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT
See drug price trends for LASTACAFT.
The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: Poland Patent 1,999,109
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can AMYVID (florbetapir f-18) generic drug versions launch?
Generic name: florbetapir f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: Poland Patent 2,363,392
AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.
This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID
The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: Poland Patent 1,978,015
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can TRIFERIC (ferric pyrophosphate citrate) generic drug versions launch?
Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: Poland Patent 2,016,940
TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.
This drug has thirteen patent family members in eleven countries.
See drug price trends for TRIFERIC.
The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.
When can KYBELLA (deoxycholic acid) generic drug versions launch?
Generic name: deoxycholic acid
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Poland Patent 2,407,475
KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA
The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.
When can RASUVO (methotrexate) generic drug versions launch?
Generic name: methotrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 21, 2026
Generic Entry Controlled by: Poland Patent 2,046,332
This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO
See drug price trends for RASUVO.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.
When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: Poland Patent 2,102,224
This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR
See drug price trends for INVOKAMET XR.
The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can MYRBETRIQ (mirabegron) generic drug versions launch?
Generic name: mirabegron
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2027
Generic Entry Controlled by: Poland Patent 2,216,021
MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has fifty-three patent family members in twenty-five countries. There has been litigation on patents covering MYRBETRIQ
See drug price trends for MYRBETRIQ.
The generic ingredient in MYRBETRIQ is mirabegron. There are nineteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the mirabegron profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: Poland Patent 2,073,795
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2026
Generic Entry Controlled by: Poland Patent 2,200,593
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can VANTRELA ER (hydrocodone bitartrate) generic drug versions launch?
Generic name: hydrocodone bitartrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 14, 2027
Generic Entry Controlled by: Poland Patent 2,692,341
VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER
The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.
When can BELSOMRA (suvorexant) generic drug versions launch?
Generic name: suvorexant
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: Poland Patent 2,089,382
This drug has seventy-five patent family members in thirty-six countries.
See drug price trends for BELSOMRA.
The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.
When can BRILINTA (ticagrelor) generic drug versions launch?
Generic name: ticagrelor
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 21, 2026
Generic Entry Controlled by: Poland Patent 2,056,832
This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA
See drug price trends for BRILINTA.
The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.
When can FARXIGA (dapagliflozin) generic drug versions launch?
Generic name: dapagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Poland Patent 2,069,374
This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA
See drug price trends for FARXIGA.
The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.
When can GLYXAMBI (empagliflozin; linagliptin) generic drug versions launch?
Generic name: empagliflozin; linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Poland Patent 2,187,879
This drug has five hundred and twenty-one patent family members in forty-five countries. There has been litigation on patents covering GLYXAMBI
See drug price trends for GLYXAMBI.
The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; linagliptin profile page.
When can INLYTA (axitinib) generic drug versions launch?
Generic name: axitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 05, 2027
Generic Entry Controlled by: Poland Patent 2,134,702
INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA
See drug price trends for INLYTA.
The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.
When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 04, 2026
Generic Entry Controlled by: Poland Patent 2,102,224
This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET
See drug price trends for INVOKAMET.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 2,173,752
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 2,740,731
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JAKAFI (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 3,070,090
JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI
See drug price trends for JAKAFI.
The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can JARDIANCE (empagliflozin) generic drug versions launch?
Generic name: empagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Poland Patent 2,187,879
This drug has four hundred and eighteen patent family members in forty-six countries. There has been litigation on patents covering JARDIANCE
See drug price trends for JARDIANCE.
The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the empagliflozin profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 01, 2026
Generic Entry Controlled by: Poland Patent 2,261,215
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can LETAIRIS (ambrisentan) generic drug versions launch?
Generic name: ambrisentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Poland Patent 2,101,777
LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS
See drug price trends for LETAIRIS.
The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.
When can OPSUMIT (macitentan) generic drug versions launch?
Generic name: macitentan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Poland Patent 2,059,246
OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT
See drug price trends for OPSUMIT.
The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.
When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch?
Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Poland Patent 2,107,905
This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI
See drug price trends for OSENI.
The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 26, 2027
Generic Entry Controlled by: Poland Patent 1,989,182
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can PROMACTA (eltrombopag olamine) generic drug versions launch?
Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 01, 2027
Generic Entry Controlled by: Poland Patent 2,152,237
PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.
This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA
See drug price trends for PROMACTA.
The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.
When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?
Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Poland Patent 2,069,374
This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN
See drug price trends for QTERN.
The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 01, 2026
Generic Entry Controlled by: Poland Patent 2,261,215
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAVAYSA (edoxaban tosylate) generic drug versions launch?
Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: Poland Patent 2,140,867
This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA
See drug price trends for SAVAYSA.
The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch?
Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 05, 2026
Generic Entry Controlled by: Poland Patent 2,086,940
SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.
This drug has ninety-seven patent family members in thirty-nine countries.
See drug price trends for SIRTURO.
The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: Poland Patent 2,023,902
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: Poland Patent 2,277,509
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRADJENTA (linagliptin) generic drug versions launch?
Generic name: linagliptin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: Poland Patent 2,283,819
This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA
See drug price trends for TRADJENTA.
The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.
When can TRINTELLIX (vortioxetine hydrobromide) generic drug versions launch?
Generic name: vortioxetine hydrobromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2027
Generic Entry Controlled by: Poland Patent 2,044,043
This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX
See drug price trends for TRINTELLIX.
The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,029,524
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can XADAGO (safinamide mesylate) generic drug versions launch?
Generic name: safinamide mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Poland Patent 2,474,521
This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO
See drug price trends for XADAGO.
The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.
When can ZUBSOLV (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Poland Patent 2,101,740
This drug has sixty-two patent family members in thirty-two countries. There has been litigation on patents covering ZUBSOLV
See drug price trends for ZUBSOLV.
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can ZEMDRI (plazomicin sulfate) generic drug versions launch?
Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 21, 2027
Generic Entry Controlled by: Poland Patent 2,217,610
ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries. There has been litigation on patents covering ZEMDRI
See drug price trends for ZEMDRI.
The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this generic product. Additional details are available on the plazomicin sulfate profile page.
When can BYFAVO (remimazolam besylate) generic drug versions launch?
Generic name: remimazolam besylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Poland Patent 2,081,921
BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.
This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO
See drug price trends for BYFAVO.
The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,164,467
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRELSTAR (triptorelin pamoate) generic drug versions launch?
Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Poland Patent 2,500,014
TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.
This drug has forty-seven patent family members in thirty-two countries.
See drug price trends for TRELSTAR.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.
When can TRIFERIC AVNU (ferric pyrophosphate citrate) generic drug versions launch?
Generic name: ferric pyrophosphate citrate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: Poland Patent 2,016,940
TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.
This drug has twelve patent family members in eleven countries.
See drug price trends for TRIFERIC AVNU.
The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Poland Patent 2,503,004
This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Poland Patent 2,503,005
This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can WINLEVI (clascoterone) generic drug versions launch?
Generic name: clascoterone
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Poland Patent 2,966,175
This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI
See drug price trends for WINLEVI.
The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,164,844
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?
Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Poland Patent 2,754,660
TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO
See drug price trends for TEPMETKO.
The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.
When can KORSUVA (difelikefalin acetate) generic drug versions launch?
Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Poland Patent 2,064,228
KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.
This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA
See drug price trends for KORSUVA.
The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.
When can OPZELURA (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 2,173,752
This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA
See drug price trends for OPZELURA.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can OPZELURA (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 2,740,731
This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA
See drug price trends for OPZELURA.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can OPZELURA (ruxolitinib phosphate) generic drug versions launch?
Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Poland Patent 3,070,090
This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA
See drug price trends for OPZELURA.
The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Poland Patent 2,091,940
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can XERMELO (telotristat etiprate) generic drug versions launch?
Generic name: telotristat etiprate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Poland Patent 3,176,159
XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.
This drug has seventy patent family members in twenty-nine countries.
See drug price trends for XERMELO.
The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.
When can LOCAMETZ (gallium ga-68 gozetotide) generic drug versions launch?
Generic name: gallium ga-68 gozetotide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 17, 2027
Generic Entry Controlled by: Poland Patent 2,187,965
LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.
This drug has fifty-four patent family members in sixteen countries.
See drug price trends for LOCAMETZ.
The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the gallium ga-68 gozetotide profile page.
When can INPEFA (sotagliflozin) generic drug versions launch?
Generic name: sotagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 27, 2027
Generic Entry Controlled by: Poland Patent 2,089,361
This drug has eighty-one patent family members in thirty-three countries.
See drug price trends for INPEFA.
The generic ingredient in INPEFA is sotagliflozin. One supplier is listed for this generic product. Additional details are available on the sotagliflozin profile page.
When can INPEFA (sotagliflozin) generic drug versions launch?
Generic name: sotagliflozin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: September 29, 2026
Generic Entry Controlled by: Poland Patent 2,308,841
This drug has eighty-one patent family members in thirty-three countries.
See drug price trends for INPEFA.
The generic ingredient in INPEFA is sotagliflozin. One supplier is listed for this generic product. Additional details are available on the sotagliflozin profile page.
When can VAFSEO (vadadustat) generic drug versions launch?
Generic name: vadadustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2026
Generic Entry Controlled by: Poland Patent 2,044,005
VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.
This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO
The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.
When can VAFSEO (vadadustat) generic drug versions launch?
Generic name: vadadustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2026
Generic Entry Controlled by: Poland Patent 3,026,044
VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.
This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO
The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.
When can VAFSEO (vadadustat) generic drug versions launch?
Generic name: vadadustat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2026
Generic Entry Controlled by: Poland Patent 3,357,911
VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.
This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO
The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Poland Patent 1,948,158
This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE
See drug price trends for ENTRESTO SPRINKLE.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can OPSYNVI (macitentan; tadalafil) generic drug versions launch?
Generic name: macitentan; tadalafil
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Poland Patent 2,059,246
OPSYNVI is a drug marketed by Actelion. There are three patents protecting this drug.
This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSYNVI
See drug price trends for OPSYNVI.
The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan; tadalafil profile page.